AlzChem Group (ACT) Fair Value & Analysis
Basic Materials · DE · Market cap €1.9B
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 5 days ago
Share price −7.3% over the past month.
Price vs Fair Value (12 months)
12‑month range €133.64 – €207.24 · fair‑value band €53.83 – €117.75 · the €187.00 price screens above the €82.17 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
AlzChem Group (ACT) currently trades at €187.00, while our model-based Fair Value estimate is €82.17 — implying the stock looks roughly 56.1% overvalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, AlzChem Group generated revenue of €375M at a net margin of 5.8%. Revenue grew 6.3% year over year. It earns a return on equity of 27.3%. The balance sheet holds a net cash position of €26.3M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
AlzChem Group AG, together with its subsidiaries, develops, produces, and markets a range of chemical specialties in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals segment sells specialty chemical products that are used in the chemical, food, animal feed, defence technology, and renewable energies industries. This segment manufactures composite materials and adhesives, as well as silicon nitride for ceramics; and photovoltaic modules in the solar industry. The Basics & Intermediates segment produces raw materials for specialty chemicals; and products for agriculture and metallurgy, as well as intermediates for the chemical industry that are produced from lime, carbon, and electricity. This segment also engages in the production and sale of guanidine salts as a raw material for agrochemicals and active pharmaceutical ingredie…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
AlzChem Group reported revenue of €562M in FY2025 versus €422M in FY2021, a compound +7.4%/yr. Reported net income was €63.5M in FY2025, compounding +23.1%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $512.26 | $225.55 | -56% |
| L'Air Liquide S.A AIQUY | $37.93 | $15.46 | -59% |
| Air Products and Chemicals, Inc A1PD34 | R$360.05 | R$108.63 | -70% |
| Intercontinental Exchange, Inc I1CE34 | R$334.47 | R$67.12 | -80% |
| Wanhua Chemical Group 600309 | ¥74.30 | ¥68.03 | -8% |
| Asian Paints Limited ASIANPAINT | ₹2,715 | ₹655.71 | -76% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is AlzChem Group (ACT) undervalued?
What is the fair value of ACT?
What is the quality score of ACT?
What is the revenue of AlzChem Group (ACT)?
What is the net profit margin of ACT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.